Egyptian molecular diagnostics startup Reme-D has secured $1.45 million in a pre-Series A funding round led by Anara Impact Capital, with contributions from the Global Innovation Fund and Africa Health Ventures. The funding will enable Reme-D to enhance manufacturing and develop new diagnostic products, as well as expand its presence across African markets. The company aims to make high-quality molecular diagnostics more accessible, particularly for diseases like tuberculosis, HIV, and cancer. With over 550,000 tests supplied across Egypt, Kenya, and Sudan, Reme-D is also innovating with heat-stable products and mobile laboratories. CEO Salma Tamam emphasizes the company’s mission to improve healthcare access in underserved regions, highlighting the growing importance of local biotechnology in Africa’s healthcare landscape.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://techbuild.africa/reme-d-1-45m-african-biotech-local-diagnostic/
